Augment Biologics Inc.

Augment Biologics Inc. is a biotech startup focused on glycoprotein-drug design using its innovative GlycoTemplating platform to enhance the efficacy and safety of biologics. The company serves clients primarily within the biopharmaceutical sector. Founded in 2024, Augment Biologics Inc.

operates out of Cambridge, US, specializing in the development of glycoprotein-drug design. The company has engaged in one deal to date, with its most recent deal occurring on August 13, 2025. It was established by individuals with backgrounds in biotechnology, but specific founder details are not disclosed. Augment Biologics Inc.

specializes in glycoprotein-drug design through its proprietary platform, GlycoTemplating. This innovative technology allows for the site-specific incorporation of glycans into the primary sequences of biologics, enhancing their efficacy, safety, and durability. By addressing the challenges associated with traditional glycoengineering methods, GlycoTemplating transforms glycans from manufacturing risks into strategic design opportunities. The company targets a diverse range of applications, including antibody, protein, and peptide engineering, as well as long-term initiatives in RNA therapeutics, delivery vehicles, and vaccine development.

Augment’s offerings appeal to a broad clientele within the biopharmaceutical sector, including biotech firms and pharmaceutical companies primarily operating in North America and Europe. Augment Biologics Inc. employs a transactional model primarily centered around collaborations and partnerships with biopharmaceutical entities. The company engages in B2B transactions, providing access to its GlycoTemplating platform under contractual agreements that may involve licensing fees or revenue-sharing arrangements based on the commercialization of developed biologics.

Such partnerships may include tiered pricing structures that reflect the scale and complexity of the glycoprotein-drug development services provided. Specific flagship products associated with this platform enhance drug design processes, but detailed pricing information regarding individual services and contractual terms is not publicly disclosed. This transactional framework supports Augment’s revenue generation by facilitating the integration of their advanced glycoengineering technology into clients' existing drug development pipelines. In August 2025, Augment Biologics Inc.

raised an undisclosed amount of Seed funding from new investor SOSV. The company plans to utilize this funding to accelerate the development of new glycoprotein-drug products designed to enter the market by late 2026. Additionally, Augment is exploring expansion into European markets, with a targeted timeline for establishing partnerships and collaborations by mid-2026.